Insider · CIK 0001480208
Paul Mintz
Files at AURX (Nuo Therapeutics, Inc.). First filing -, latest -.
In brief
Paul Mintz files SEC Form 4 as director at AURX (Nuo Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Paul Mintz has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Option to Purchase Common Stockderivative | +30,000 | $0.00 | $0 | 30,000 | Jul 2, 2026 |
| Dec 9, 2025 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +50,000 | $0.40 | $20k | 117,385 | Dec 11, 2025 |
| Dec 9, 2025 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +50,000 | $0.40 | $20k | 117,385 | Dec 11, 2025 |
| Dec 9, 2025 | AURX Nuo Therapeutics, Inc. | FTax withholding Common Stock | -9,091 | $2.20 | $20k | 108,294 | Dec 11, 2025 |
| Dec 9, 2025 | AURX Nuo Therapeutics, Inc. | FTax withholding Common Stock | -9,091 | $2.20 | $20k | 108,294 | Dec 11, 2025 |
| Dec 31, 2018 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to purchase common stockderivative | -50,000 | $0.00 | $0 | 0 | Dec 11, 2025 |
| Dec 31, 2018 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to purchase common stockderivative | -50,000 | $0.00 | $0 | 0 | Dec 11, 2025 |
| Aug 1, 2025 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +87,500 | $0.40 | $35k | 87,500 | Aug 4, 2025 |
| Aug 1, 2025 | AURX Nuo Therapeutics, Inc. | FTax withholding Common Stock | -20,115 | $1.74 | $35k | 67,385 | Aug 4, 2025 |
| Aug 9, 2018 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to purchase common stockderivative | -87,500 | $0.00 | $0 | 0 | Aug 4, 2025 |
Questions about Paul Mintz
Answered from the filings on this page, as of the latest one.
Is Paul Mintz buying or selling?
Paul Mintz has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Paul Mintz's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul Mintz has 0.
Where does Paul Mintz file Form 4?
Paul Mintz has filed Form 4 at AURX (Nuo Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.